You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCaptopril
Accession NumberDB01197  (APRD00164)
TypeSmall Molecule
GroupsApproved
DescriptionCaptopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension.
Structure
Thumb
Synonyms
(2S)-1-[(2S)-2-Methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
Acepress
Apopril
Capoten
Captolane
Captoprilum
Captopryl
Captoril
Cesplon
CP
D-2-Methyl-3-mercaptopropanoyl-L-proline
D-3-Mercapto-2-methylpropanoyl-L-proline
Dilabar
Garranil
Hypertil
L-Captopril
Lopirin
Tenosbon
Tensobon
Tensoprel
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bci Captopril Tabletstablet25 mgoralBaker Cummins IncNot applicableNot applicableCanada
Bci Captopril Tabletstablet50 mgoralBaker Cummins IncNot applicableNot applicableCanada
Bci Captopril Tabletstablet100 mgoralBaker Cummins IncNot applicableNot applicableCanada
Bci Captopril Tabletstablet12.5 mgoralBaker Cummins IncNot applicableNot applicableCanada
Capoten Tab 100mgtablet100 mgoralBristol Myers Squibb Canada1981-12-312008-02-05Canada
Capoten Tab 12.5mgtablet12.5 mgoralBristol Myers Squibb Canada1990-12-312009-06-29Canada
Capoten Tab 25mgtablet25 mgoralBristol Myers Squibb Canada1981-12-312011-11-01Canada
Capoten Tab 50mgtablet50 mgoralBristol Myers Squibb Canada1981-12-312010-12-16Canada
Captopriltablet25 mgoralSorres Pharma Inc2000-10-262014-06-20Canada
Captopriltablet100 mgoralPharmel Inc1998-09-03Not applicableCanada
Captopriltablet12.5 mgoralPharmel Inc1998-09-03Not applicableCanada
Captopriltablet50 mgoralSorres Pharma Inc2000-10-262014-06-20Canada
Captopriltablet25 mgoralPharmel Inc1998-09-03Not applicableCanada
Captopriltablet100 mgoralSorres Pharma Inc2000-10-262014-06-20Canada
Captopriltablet12.5 mgoralSorres Pharma Inc2000-10-262014-06-20Canada
Captopriltablet50 mgoralPharmel Inc1998-09-03Not applicableCanada
Captopril Tabletstablet12.5 mgoralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Captopril Tabletstablet25 mgoralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Captopril Tabletstablet50 mgoralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Captopril Tabletstablet100 mgoralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Captopril-100 Tab 100mgtablet100 mgoralPro Doc Limitee1991-12-312000-07-31Canada
Captopril-12.5 Tab 12.5mgtablet12.5 mgoralPro Doc Limitee1991-12-312009-07-23Canada
Captopril-25 Tab 25mgtablet25 mgoralPro Doc Limitee1991-12-312012-07-23Canada
Captopril-50 Tab 50mgtablet50 mgoralPro Doc Limitee1991-12-312009-07-23Canada
Captriltablet12.5 mgoralTechnilab Pharma Inc.1998-06-302004-08-03Canada
Captriltablet25 mgoralTechnilab Pharma Inc.1998-06-302004-08-03Canada
Captriltablet50 mgoralTechnilab Pharma Inc.1998-06-302004-08-03Canada
Captriltablet100 mgoralTechnilab Pharma Inc.1998-06-302004-08-03Canada
Dom-captopriltablet100 mgoralDominion Pharmacal1998-09-17Not applicableCanada
Dom-captopriltablet12.5 mgoralDominion Pharmacal1998-09-17Not applicableCanada
Dom-captopriltablet25 mgoralDominion Pharmacal1998-09-17Not applicableCanada
Dom-captopriltablet50 mgoralDominion Pharmacal1998-09-17Not applicableCanada
Ftp-captopriltablet12.5 mgoralFtp Pharmacal Inc.1998-10-092004-08-03Canada
Ftp-captopriltablet25 mgoralFtp Pharmacal Inc.1998-10-092004-08-03Canada
Ftp-captopriltablet50 mgoralFtp Pharmacal Inc.1998-10-092004-08-03Canada
Med Captopril - Tab 12.5mgtablet12.5 mgoralMedican Pharma Incorporated1996-07-302011-03-29Canada
Med Captopril - Tab 100mgtablet100 mgoralMedican Pharma Incorporated1996-07-092011-03-29Canada
Med Captopril - Tab 25mgtablet25 mgoralMedican Pharma Incorporated1996-08-222011-03-29Canada
Med Captopril - Tab 50mgtablet50 mgoralMedican Pharma Incorporated1996-07-302011-03-29Canada
Mylan-captopriltablet12.5 mgoralMylan Pharmaceuticals Ulc1995-12-31Not applicableCanada
Mylan-captopriltablet50 mgoralMylan Pharmaceuticals Ulc1995-12-31Not applicableCanada
Mylan-captopriltablet100 mgoralMylan Pharmaceuticals Ulc1995-12-31Not applicableCanada
Mylan-captopriltablet25 mgoralMylan Pharmaceuticals Ulc1995-12-31Not applicableCanada
Novo-captoriltablet6.25 mgoralNovopharm Limited1998-06-022005-08-10Canada
Nu-capto Tab 100mgtablet100 mgoralNu Pharm Inc1991-12-312012-09-04Canada
Nu-capto Tab 12.5mgtablet12.5 mgoralNu Pharm Inc1991-12-312012-09-04Canada
Nu-capto Tab 25mgtablet25 mgoralNu Pharm Inc1991-12-312012-09-04Canada
Nu-capto Tab 50mgtablet50 mgoralNu Pharm Inc1991-12-312012-09-04Canada
Orb-captopriltablet25 mgoralOrbus Pharma IncNot applicableNot applicableCanada
Orb-captopriltablet50 mgoralOrbus Pharma IncNot applicableNot applicableCanada
Penta-captopril Tabletstablet12.5 mgoralPentapharm Ltd.Not applicableNot applicableCanada
Penta-captopril Tabletstablet25 mgoralPentapharm Ltd.Not applicableNot applicableCanada
Penta-captopril Tabletstablet50 mgoralPentapharm Ltd.Not applicableNot applicableCanada
Penta-captopril Tabletstablet100 mgoralPentapharm Ltd.Not applicableNot applicableCanada
PMS-captopril - Tab 12.5mgtablet12.5 mgoralPharmascience Inc1998-06-17Not applicableCanada
PMS-captopril - Tab 25mgtablet25 mgoralPharmascience Inc1998-06-17Not applicableCanada
PMS-captopril - Tab 50mgtablet50 mgoralPharmascience Inc1998-06-17Not applicableCanada
PMS-captopril - Tab 100mgtablet100 mgoralPharmascience Inc1998-06-17Not applicableCanada
Ratio-captopril Tab 100mgtablet100 mgoralRatiopharm Inc Division Of Teva Canada Limited1990-12-312006-08-04Canada
Ratio-captopril Tab 12.5mgtablet12.5 mgoralRatiopharm Inc Division Of Teva Canada Limited1990-12-312006-08-04Canada
Ratio-captopril Tab 25mgtablet25 mgoralRatiopharm Inc Division Of Teva Canada Limited1990-12-312006-08-04Canada
Ratio-captopril Tab 50mgtablet50 mgoralRatiopharm Inc Division Of Teva Canada Limited1990-12-312006-08-04Canada
Teva-captopriltablet12.5 mgoralTeva Canada Limited1991-12-31Not applicableCanada
Teva-captopriltablet25 mgoralTeva Canada Limited1991-12-31Not applicableCanada
Teva-captopriltablet50 mgoralTeva Canada Limited1991-12-31Not applicableCanada
Teva-captopriltablet100 mgoralTeva Canada Limited1991-12-31Not applicableCanada
Tria-captopril 100mg Tablettablet100 mgoralLaboratoires Trianon IncNot applicableNot applicableCanada
Tria-captopril 12.5mg Tablettablet12.5 mgoralLaboratoires Trianon IncNot applicableNot applicableCanada
Tria-captopril 25mg Tablettablet25 mgoralLaboratoires Trianon IncNot applicableNot applicableCanada
Tria-captopril 50mg Tablettablet50 mgoralLaboratoires Trianon IncNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-capto Tab 100mgtablet100 mgoralApotex Inc1990-12-31Not applicableCanada
Apo-capto Tab 12.5mgtablet12.5 mgoralApotex Inc1990-12-31Not applicableCanada
Apo-capto Tab 25mgtablet25 mgoralApotex Inc1990-12-31Not applicableCanada
Apo-capto Tab 50mgtablet50 mgoralApotex Inc1990-12-31Not applicableCanada
Apo-capto Tab 6.25mgtablet6.25 mgoralApotex Inc1992-12-31Not applicableCanada
Captopriltablet100 mg/1oralMylan Pharmaceuticals Inc.1996-02-13Not applicableUs
Captopriltablet50 mg/1oralPreferred Pharmaceuticals, Inc.2012-12-13Not applicableUs
Captopriltablet100 mg/1oralApotex Corp.2005-12-07Not applicableUs
Captopriltablet12.5 mg/1oralWockhardt USA LLC.1997-03-28Not applicableUs
Captopriltablet25 mg/1oralCardinal Health2004-02-16Not applicableUs
Captopriltablet50 mg/1oralUnit Dose Services1996-02-13Not applicableUs
Captopriltablet100 mg/1oralAidarex Pharmaceuticals LLC1997-03-28Not applicableUs
Captopriltablet12.5 mg/1oralWest Ward Pharmaceuticals Corp1996-02-13Not applicableUs
Captopriltablet12.5 mg/1oralbryant ranch prepack1996-02-13Not applicableUs
Captopriltablet12.5 mg/1oralGolden State Medical Supply, Inc.1996-02-13Not applicableUs
Captopriltablet100 mg/1oralWindlas Healthcare (P) Ltd.1997-03-28Not applicableUs
Captopriltablet100 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Captopriltablet12.5 mg/1oralGLENVIEW PHARMA INC.1997-03-28Not applicableUs
Captopriltablet25 mg/1oralREMEDYREPACK INC.2014-09-15Not applicableUs
Captopriltablet25 mg/1oralA S Medication Solutions1996-02-13Not applicableUs
Captopriltablet12.5 mg/1oralWockhardt Limited1997-03-28Not applicableUs
Captopriltablet25 mg/1oralMylan Institutional Inc.1996-02-14Not applicableUs
Captopriltablet50 mg/1oralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Captopriltablet25 mg/1oralLegacy Pharmaceutical Packaging2009-09-11Not applicableUs
Captopriltablet12.5 mg/1oralApotex Corp.2005-12-07Not applicableUs
Captopriltablet50 mg/1oralCarilion Materials Management1996-02-13Not applicableUs
Captopriltablet50 mg/1oralPhysicians Total Care, Inc.1996-08-05Not applicableUs
Captopriltablet12.5 mg/1oralPd Rx Pharmaceuticals, Inc.2011-05-04Not applicableUs
Captopriltablet12.5 mg/1oralMylan Pharmaceuticals Inc.1996-02-13Not applicableUs
Captopriltablet25 mg/1oralCardinal Health2011-04-29Not applicableUs
Captopriltablet12.5 mg/1oralUnit Dose Services1997-03-28Not applicableUs
Captopriltablet12.5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1997-03-28Not applicableUs
Captopriltablet25 mg/1oralPreferred Pharmaceuticals, Inc.2012-12-13Not applicableUs
Captopriltablet12.5 mg/1oralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs
Captopriltablet25 mg/1oralWockhardt USA LLC.1997-03-28Not applicableUs
Captopriltablet25 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Captopriltablet25 mg/1oralAidarex Pharmaceuticals LLC1997-03-28Not applicableUs
Captopriltablet25 mg/1oralWest Ward Pharmaceuticals Corp1996-02-13Not applicableUs
Captopriltablet15 mg/1oralRed Pharm Drug Inc.1996-02-13Not applicableUs
Captopriltablet25 mg/1oralGolden State Medical Supply, Inc.1996-02-13Not applicableUs
Captopriltablet25 mg/1oralGLENVIEW PHARMA INC.1997-03-28Not applicableUs
Captopriltablet25 mg/1oralbryant ranch prepack1996-02-13Not applicableUs
Captopriltablet12.5 mg/1oralWindlas Healthcare (P) Ltd.1997-03-28Not applicableUs
Captopriltablet25 mg/1oralWockhardt Limited1997-03-28Not applicableUs
Captopriltablet25 mg/1oralREMEDYREPACK INC.2014-01-30Not applicableUs
Captopriltablet25 mg/1oralRebel Distributors Corp1996-02-13Not applicableUs
Captopriltablet50 mg/1oralLegacy Pharmaceutical Packaging2009-09-11Not applicableUs
Captopriltablet25 mg/1oralApotex Corp.2005-12-07Not applicableUs
Captopriltablet25 mg/1oralREMEDYREPACK INC.2016-03-11Not applicableUs
Captopriltablet12.5 mg/1oralCardinal Health2004-02-16Not applicableUs
Captopriltablet50 mg/1oralREMEDYREPACK INC.2011-06-16Not applicableUs
Captopriltablet25 mg/1oralMylan Pharmaceuticals Inc.1996-02-13Not applicableUs
Captopriltablet50 mg/1oralSt Marys Medical Park Pharmacy2014-01-16Not applicableUs
Captopriltablet50 mg/1oralWockhardt USA LLC.1997-03-28Not applicableUs
Captopriltablet12.5 mg/1oralCardinal Health2011-04-29Not applicableUs
Captopriltablet25 mg/1oralUnit Dose Services1996-02-13Not applicableUs
Captopriltablet25 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1997-03-28Not applicableUs
Captopriltablet50 mg/1oralPreferred Pharmaceuticals, Inc.1996-02-13Not applicableUs
Captopriltablet50 mg/1oralRed Pharm Drug Inc.1996-02-13Not applicableUs
Captopriltablet50 mg/1oralGolden State Medical Supply, Inc.1996-02-13Not applicableUs
Captopriltablet50 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Captopriltablet25 mg/1oralRebel Distributors Corp1997-03-28Not applicableUs
Captopriltablet50 mg/1oralWest Ward Pharmaceuticals Corp1996-02-13Not applicableUs
Captopriltablet50 mg/1oralGLENVIEW PHARMA INC.1997-03-28Not applicableUs
Captopriltablet100 mg/1oralbryant ranch prepack1996-02-13Not applicableUs
Captopriltablet25 mg/1oralWindlas Healthcare (P) Ltd.1997-03-28Not applicableUs
Captopriltablet50 mg/1oralWockhardt Limited1997-03-28Not applicableUs
Captopriltablet12.5 mg/1oralAidarex Pharmaceuticals LLC1997-03-28Not applicableUs
Captopriltablet50 mg/1oralRebel Distributors Corp1996-02-13Not applicableUs
Captopriltablet100 mg/1oralLegacy Pharmaceutical Packaging2009-09-11Not applicableUs
Captopriltablet50 mg/1oralApotex Corp.2005-12-07Not applicableUs
Captopriltablet100 mg/1oralState of Florida DOH Central Pharmacy2009-07-012016-03-02Us
Captopriltablet50 mg/1oralCardinal Health2004-02-16Not applicableUs
Captopriltablet30 mg/1oralREMEDYREPACK INC.2013-02-28Not applicableUs
Captopriltablet50 mg/1oralMylan Pharmaceuticals Inc.1996-02-13Not applicableUs
Captopriltablet25 mg/1oralPreferred Pharmaceuticals, Inc.2012-03-29Not applicableUs
Captopriltablet25 mg/1oralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs
Captopriltablet100 mg/1oralWockhardt USA LLC.1997-03-28Not applicableUs
Captopriltablet25 mg/1oralPd Rx Pharmaceuticals, Inc.1996-02-13Not applicableUs
Captopriltablet12.5 mg/1oralMylan Institutional Inc.1996-02-14Not applicableUs
Captopriltablet50 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1997-03-28Not applicableUs
Captopriltablet12.5 mg/1oralLegacy Pharmaceutical Packaging2009-09-11Not applicableUs
Captopriltablet100 mg/1oralGolden State Medical Supply, Inc.1996-02-13Not applicableUs
Captopriltablet25 mg/1oralPhysicians Total Care, Inc.1996-04-25Not applicableUs
Captopriltablet50 mg/1oralRebel Distributors Corp1997-03-28Not applicableUs
Captopriltablet100 mg/1oralWest Ward Pharmaceuticals Corp1996-02-13Not applicableUs
Captopriltablet50 mg/1oralAidarex Pharmaceuticals LLC1997-03-28Not applicableUs
Captopriltablet50 mg/1oralbryant ranch prepack2009-09-11Not applicableUs
Captopriltablet50 mg/1oralWindlas Healthcare (P) Ltd.1997-03-28Not applicableUs
Captopriltablet100 mg/1oralWockhardt Limited1997-03-28Not applicableUs
Captopriltablet50 mg/1oralState of Florida DOH Central Pharmacy2009-07-012016-03-11Us
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AcepressBernofarm (Indonesia), BMS (Italy)
AceprilBMS (United Kingdom)
AlopresinNot Available
ApoprilNot Available
CapotenBristol-Myers Squibb, Par
CaptolaneSanofi-Aventis (France)
CaptorilNovopharm (Canada)
CesplonEsteve (Spain)
DilabarQualigen (Spain)
GarranilAristegui (Spain)
HipertilNormal (Portugal)
HypertilNormal (Portugal)
LopirinBMS (Germany,Switzerland)
LoprilOrion (Finland), BMS (France)
TenosbonNot Available
TensoprelRubio (Spain)
Brand mixtures
NameLabellerIngredients
Captopril and HydrochlorothiazideMylan Phamaceuticals Inc.
SaltsNot Available
Categories
UNII9G64RSX1XD
CAS number62571-86-2
WeightAverage: 217.285
Monoisotopic: 217.077264041
Chemical FormulaC9H15NO3S
InChI KeyInChIKey=FAKRSMQSSFJEIM-RQJHMYQMSA-N
InChI
InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1
IUPAC Name
(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
SMILES
C[[email protected]](CS)C(=O)N1CCC[[email protected]]1C(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentN-acyl-alpha amino acids
Alternative Parents
Substituents
  • N-acyl-alpha-amino acid
  • Pyrrolidine carboxylic acid or derivatives
  • Pyrrolidine carboxylic acid
  • N-acylpyrrolidine
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Alkylthiol
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics). May be used to treat congestive heart failure in combination with other drugs (e.g. cardiac glycosides, diuretics, β-adrenergic blockers). May improve survival in patients with left ventricular dysfunction following myocardial infarction. May be used to treat nephropathy, including diabetic nephropathy.
PharmacodynamicsCaptopril, an ACE inhibitor, antagonizes the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may sustain its effects by causing increased vasodilation and decreased blood pressure.
Mechanism of actionThere are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Captopril, one of the few ACE inhibitors that is not a prodrug, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Captopril also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors. Captopril’s affinity for ACE is approximately 30,000 times greater than that of ATI.
Related Articles
Absorption60-75% in fasting individuals; food decreases absorption by 25-40% (some evidence indicates that this is not clinically significant)
Volume of distributionNot Available
Protein binding25-30% bound to plasma proteins, primarily albumin
Metabolism

Hepatic. Major metabolites are captopril-cysteine disulfide and the disulfide dimer of captopril. Metabolites may undergo reversible interconversion.

SubstrateEnzymesProduct
Captopril
Not Available
captopril-cysteine disulfideDetails
Route of eliminationNot Available
Half life2 hours
ClearanceNot Available
ToxicitySymptoms of overdose include emesis and decreased blood pressure. Side effects include dose-dependent rash (usually maculopapular), taste alterations, hypotension, gastric irritation, cough, and angioedema.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Captopril Action PathwayDrug actionSMP00146
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.97
Blood Brain Barrier+0.6467
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.6276
P-glycoprotein inhibitor INon-inhibitor0.8448
P-glycoprotein inhibitor IINon-inhibitor0.7415
Renal organic cation transporterNon-inhibitor0.8073
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6293
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9102
CYP450 2D6 inhibitorNon-inhibitor0.9537
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9049
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8975
Ames testNon AMES toxic0.8164
CarcinogenicityNon-carcinogens0.9434
BiodegradationNot ready biodegradable0.6577
Rat acute toxicity1.7403 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9604
hERG inhibition (predictor II)Non-inhibitor0.9118
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral100 mg
Tabletoral12.5 mg
Tabletoral25 mg
Tabletoral50 mg
Tabletoral6.25 mg
Tabletoral100 mg/1
Tabletoral12.5 mg/1
Tabletoral15 mg/1
Tabletoral25 mg/1
Tabletoral30 mg/1
Tabletoral50 mg/1
Tabletoral
Prices
Unit descriptionCostUnit
Captopril powder22.03USD g
Capoten 100 mg tablet4.53USD tablet
Capoten 12.5 mg tablet1.8USD tablet
Captopril 100 mg tablet1.53USD tablet
Captopril 50 mg tablet1.14USD tablet
Capoten 25 mg tablet1.13USD tablet
Capoten 50 mg tablet1.13USD tablet
Apo-Capto 100 mg Tablet1.09USD tablet
Mylan-Captopril 100 mg Tablet1.09USD tablet
Novo-Captoril 100 mg Tablet1.09USD tablet
Nu-Capto 100 mg Tablet1.09USD tablet
Captopril 25 mg tablet0.67USD tablet
Captopril 12.5 mg tablet0.62USD tablet
Apo-Capto 50 mg Tablet0.59USD tablet
Mylan-Captopril 50 mg Tablet0.59USD tablet
Novo-Captoril 50 mg Tablet0.59USD tablet
Nu-Capto 50 mg Tablet0.59USD tablet
Apo-Capto 25 mg Tablet0.31USD tablet
Mylan-Captopril 25 mg Tablet0.31USD tablet
Novo-Captoril 25 mg Tablet0.31USD tablet
Nu-Capto 25 mg Tablet0.31USD tablet
Apo-Capto 12.5 mg Tablet0.22USD tablet
Mylan-Captopril 12.5 mg Tablet0.22USD tablet
Novo-Captoril 12.5 mg Tablet0.22USD tablet
Nu-Capto 12.5 mg Tablet0.22USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5238924 No1993-08-242010-08-24Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point103-104Ondetti, M.A. and Cushman, D.W.; U.S. Patent 4,046,889; September 6, 1977; assigned t o E.R. Squibb & Sons, Inc. Ondetti, M.A. and Cushman, D.W.; U.S. Patent 4,105,776; August 8,1978; assigned to E.R. Squibb & Sons, Inc. Ondetti, M.A. and Cushman, D.W.; U.S. Patent 4,154,840; May 15,1979; assigned to E.R. Squibb & Sons, Inc.
water solubilityFreely solubleNot Available
logP0.34RANADIVE,SA ET AL. (1992)
Predicted Properties
PropertyValueSource
Water Solubility4.52 mg/mLALOGPS
logP1.02ALOGPS
logP0.73ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)4.02ChemAxon
pKa (Strongest Basic)-1.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area57.61 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity54.63 m3·mol-1ChemAxon
Polarizability21.72 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Charles M. Zepp, “Methods for preparing captopril and its analogues.” U.S. Patent US5166361, issued July, 1981.

US5166361
General References
  1. Atkinson AB, Robertson JI: Captopril in the treatment of clinical hypertension and cardiac failure. Lancet. 1979 Oct 20;2(8147):836-9. [PubMed:90928 ]
  2. Patchett AA, Harris E, Tristram EW, Wyvratt MJ, Wu MT, Taub D, Peterson ER, Ikeler TJ, ten Broeke J, Payne LG, Ondeyka DL, Thorsett ED, Greenlee WJ, Lohr NS, Hoffsommer RD, Joshua H, Ruyle WV, Rothrock JW, Aster SD, Maycock AL, Robinson FM, Hirschmann R, Sweet CS, Ulm EH, Gross DM, Vassil TC, Stone CA: A new class of angiotensin-converting enzyme inhibitors. Nature. 1980 Nov 20;288(5788):280-3. [PubMed:6253826 ]
  3. Smith CG, Vane JR: The discovery of captopril. FASEB J. 2003 May;17(8):788-9. [PubMed:12724335 ]
External Links
ATC CodesC09AA01C09BA01
AHFS Codes
  • 24:32.04
PDB Entries
FDA labelNot Available
MSDSDownload (37.6 KB)
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Captopril.
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Captopril.
AbirateroneThe metabolism of Captopril can be decreased when combined with Abiraterone.
AcebutololAcebutolol may increase the hypotensive activities of Captopril.
AceclofenacThe risk or severity of adverse effects can be increased when Captopril is combined with Aceclofenac.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Captopril.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Captopril.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Captopril is combined with Acetylsalicylic acid.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Captopril.
AdapaleneThe risk or severity of adverse effects can be increased when Captopril is combined with Adapalene.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Captopril.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Captopril.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Captopril.
AlfuzosinAlfuzosin may increase the hypotensive activities of Captopril.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Captopril.
AliskirenCaptopril may increase the hypotensive activities of Aliskiren.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Captopril.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Captopril.
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Captopril.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Captopril.
AlprenololAlprenolol may increase the hypotensive activities of Captopril.
Aluminum hydroxideThe serum concentration of Captopril can be decreased when it is combined with Aluminum hydroxide.
Aluminum phosphateThe serum concentration of Captopril can be decreased when it is combined with Aluminum phosphate.
AmbrisentanCaptopril may increase the hypotensive activities of Ambrisentan.
AmifostineCaptopril may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Captopril.
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Captopril.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Captopril.
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Captopril.
AmiodaroneThe metabolism of Captopril can be decreased when combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Captopril.
AmlodipineAmlodipine may increase the hypotensive activities of Captopril.
AmobarbitalAmobarbital may increase the hypotensive activities of Captopril.
Amyl NitriteThe risk or severity of adverse effects can be increased when Captopril is combined with Amyl Nitrite.
AntipyrineThe risk or severity of adverse effects can be increased when Captopril is combined with Antipyrine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Captopril.
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Captopril.
ApremilastThe risk or severity of adverse effects can be increased when Captopril is combined with Apremilast.
AprotininAprotinin may decrease the antihypertensive activities of Captopril.
ArdeparinArdeparin may increase the hyperkalemic activities of Captopril.
AripiprazoleAripiprazole may increase the hypotensive activities of Captopril.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Captopril.
ArtemetherThe metabolism of Captopril can be decreased when combined with Artemether.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Captopril.
AtenololAtenolol may increase the hypotensive activities of Captopril.
AtomoxetineThe metabolism of Captopril can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Captopril.
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Captopril.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Captopril.
AzapropazoneThe risk or severity of adverse effects can be increased when Captopril is combined with Azapropazone.
AzathioprineCaptopril may increase the myelosuppressive activities of Azathioprine.
AzelastineThe risk or severity of adverse effects can be increased when Captopril is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Captopril is combined with Azilsartan medoxomil.
BalsalazideThe risk or severity of adverse effects can be increased when Captopril is combined with Balsalazide.
BarbitalBarbital may increase the hypotensive activities of Captopril.
BemiparinBemiparin may increase the hyperkalemic activities of Captopril.
BenazeprilBenazepril may increase the hypotensive activities of Captopril.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Captopril.
BenmoxinBenmoxin may increase the hypotensive activities of Captopril.
BenoxaprofenThe risk or severity of adverse effects can be increased when Captopril is combined with Benoxaprofen.
BepridilCaptopril may increase the hypotensive activities of Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Captopril.
BetaxololBetaxolol may increase the hypotensive activities of Captopril.
BethanidineBethanidine may increase the hypotensive activities of Captopril.
BimatoprostBimatoprost may increase the hypotensive activities of Captopril.
Bismuth SubcitrateThe serum concentration of Captopril can be decreased when it is combined with Bismuth Subcitrate.
BisoprololBisoprolol may increase the hypotensive activities of Captopril.
BoceprevirThe serum concentration of Captopril can be decreased when it is combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Captopril.
BosentanBosentan may increase the hypotensive activities of Captopril.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Captopril.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Captopril.
BretyliumBretylium may increase the hypotensive activities of Captopril.
BrimonidineCaptopril may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Captopril.
BromfenacThe risk or severity of adverse effects can be increased when Captopril is combined with Bromfenac.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Captopril.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Captopril.
BupranololCaptopril may increase the hypotensive activities of Bupranolol.
BupropionThe metabolism of Captopril can be decreased when combined with Bupropion.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Captopril.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Captopril.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Captopril.
Calcium carbonateThe serum concentration of Captopril can be decreased when it is combined with Calcium carbonate.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Captopril.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Captopril.
CanagliflozinThe risk or severity of adverse effects can be increased when Captopril is combined with Canagliflozin.
CandesartanCandesartan may increase the hypotensive activities of Captopril.
CandoxatrilCandoxatril may increase the hypotensive activities of Captopril.
CarbamazepineThe metabolism of Captopril can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Captopril.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Captopril.
CaroxazoneCaroxazone may increase the hypotensive activities of Captopril.
CarprofenThe risk or severity of adverse effects can be increased when Captopril is combined with Carprofen.
CarteololCarteolol may increase the hypotensive activities of Captopril.
CarvedilolCarvedilol may increase the hypotensive activities of Captopril.
CastanospermineThe risk or severity of adverse effects can be increased when Captopril is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Captopril is combined with Celecoxib.
CelecoxibThe metabolism of Captopril can be decreased when combined with Celecoxib.
CeliprololCaptopril may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Captopril.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Captopril.
CertoparinCertoparin may increase the hyperkalemic activities of Captopril.
ChloroquineThe risk or severity of adverse effects can be increased when Captopril is combined with Chloroquine.
ChloroquineThe metabolism of Captopril can be decreased when combined with Chloroquine.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Captopril.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Captopril.
ChlorpromazineThe metabolism of Captopril can be decreased when combined with Chlorpromazine.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Captopril.
CholecalciferolThe metabolism of Captopril can be decreased when combined with Cholecalciferol.
CilazaprilCaptopril may increase the hypotensive activities of Cilazapril.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Captopril.
CimetidineThe metabolism of Captopril can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Captopril can be decreased when combined with Cinacalcet.
CiprofloxacinCaptopril may increase the arrhythmogenic activities of Ciprofloxacin.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Captopril.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Captopril.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Captopril.
CitalopramThe metabolism of Captopril can be decreased when combined with Citalopram.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Captopril.
ClemastineThe metabolism of Captopril can be decreased when combined with Clemastine.
ClevidipineThe risk or severity of adverse effects can be increased when Captopril is combined with Clevidipine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Captopril.
ClobazamThe metabolism of Captopril can be decreased when combined with Clobazam.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Captopril.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Captopril.
ClomipramineThe metabolism of Captopril can be decreased when combined with Clomipramine.
ClonidineClonidine may increase the hypotensive activities of Captopril.
ClonixinThe risk or severity of adverse effects can be increased when Captopril is combined with Clonixin.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Captopril.
ClotrimazoleThe metabolism of Captopril can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Captopril.
ClozapineThe metabolism of Captopril can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Captopril can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Captopril.
CocaineThe metabolism of Captopril can be decreased when combined with Cocaine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Captopril.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Captopril.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Captopril.
CryptenamineCryptenamine may increase the hypotensive activities of Captopril.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Captopril.
CyclophosphamideThe risk or severity of adverse effects can be increased when Captopril is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Captopril.
CyclothiazideCyclothiazide may increase the hypotensive activities of Captopril.
D-LimoneneThe risk or severity of adverse effects can be increased when Captopril is combined with D-Limonene.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Captopril.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Captopril.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Captopril.
DalteparinDalteparin may increase the hyperkalemic activities of Captopril.
DapagliflozinThe risk or severity of adverse effects can be increased when Captopril is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Captopril.
DarifenacinThe metabolism of Captopril can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Captopril can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Captopril.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Captopril.
DebrisoquinCaptopril may increase the hypotensive activities of Debrisoquin.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Captopril.
DelavirdineThe metabolism of Captopril can be decreased when combined with Delavirdine.
DeserpidineCaptopril may increase the hypotensive activities of Deserpidine.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Captopril.
DesipramineThe metabolism of Captopril can be decreased when combined with Desipramine.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Captopril.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Captopril.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Captopril.
DiazoxideDiazoxide may increase the hypotensive activities of Captopril.
DiclofenacThe risk or severity of adverse effects can be increased when Captopril is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Captopril.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Captopril.
DiflunisalThe risk or severity of adverse effects can be increased when Captopril is combined with Diflunisal.
DiflunisalDiflunisal may decrease the antihypertensive activities of Captopril.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Captopril.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Captopril.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Captopril.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Captopril.
DiltiazemDiltiazem may increase the hypotensive activities of Captopril.
DinutuximabThe risk or severity of adverse effects can be increased when Captopril is combined with Dinutuximab.
DiphenhydramineThe metabolism of Captopril can be decreased when combined with Diphenhydramine.
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Captopril.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Captopril.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Captopril.
DorzolamideDorzolamide may increase the hypotensive activities of Captopril.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Captopril.
DoxazosinDoxazosin may increase the hypotensive activities of Captopril.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Captopril.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Captopril.
DronedaroneThe metabolism of Captopril can be decreased when combined with Dronedarone.
DrospirenoneCaptopril may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Captopril is combined with Droxicam.
DuloxetineCaptopril may increase the orthostatic hypotensive activities of Duloxetine.
DuloxetineThe metabolism of Captopril can be decreased when combined with Duloxetine.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Captopril.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Captopril.
EfonidipineCaptopril may increase the hypotensive activities of Efonidipine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Captopril.
EliglustatThe metabolism of Captopril can be decreased when combined with Eliglustat.
EmpagliflozinThe risk or severity of adverse effects can be increased when Captopril is combined with Empagliflozin.
EnalaprilEnalapril may increase the hypotensive activities of Captopril.
EnalaprilatCaptopril may increase the hypotensive activities of Enalaprilat.
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Captopril.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Captopril.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Captopril.
EpirizoleThe risk or severity of adverse effects can be increased when Captopril is combined with Epirizole.
EplerenoneEplerenone may increase the hyperkalemic activities of Captopril.
EplerenoneThe risk or severity of adverse effects can be increased when Captopril is combined with Eplerenone.
EpoprostenolCaptopril may increase the hypotensive activities of Epoprostenol.
EprosartanEprosartan may increase the hypotensive activities of Captopril.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Captopril.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Captopril.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Captopril.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Captopril.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Captopril.
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Captopril.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Captopril.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Captopril.
EstriolThe serum concentration of Estriol can be increased when it is combined with Captopril.
EstroneThe serum concentration of Estrone can be increased when it is combined with Captopril.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Captopril.
EtanerceptThe risk or severity of adverse effects can be increased when Captopril is combined with Etanercept.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Captopril.
EtodolacThe risk or severity of adverse effects can be increased when Captopril is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Captopril is combined with Etofenamate.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Captopril.
EtoricoxibThe risk or severity of adverse effects can be increased when Captopril is combined with Etoricoxib.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Captopril.
Evening primrose oilThe risk or severity of adverse effects can be increased when Captopril is combined with Evening primrose oil.
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Captopril.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Captopril.
exisulindThe risk or severity of adverse effects can be increased when Captopril is combined with exisulind.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Captopril.
FelodipineFelodipine may increase the hypotensive activities of Captopril.
FenbufenThe risk or severity of adverse effects can be increased when Captopril is combined with Fenbufen.
FenoldopamFenoldopam may increase the hypotensive activities of Captopril.
FenoprofenThe risk or severity of adverse effects can be increased when Captopril is combined with Fenoprofen.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Captopril.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Captopril.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Captopril.
FloctafenineThe risk or severity of adverse effects can be increased when Captopril is combined with Floctafenine.
FlunixinThe risk or severity of adverse effects can be increased when Captopril is combined with Flunixin.
FluoxetineThe metabolism of Captopril can be decreased when combined with Fluoxetine.
FlurbiprofenThe risk or severity of adverse effects can be increased when Captopril is combined with Flurbiprofen.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Captopril.
FluvoxamineThe metabolism of Captopril can be decreased when combined with Fluvoxamine.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Captopril.
FosinoprilFosinopril may increase the hypotensive activities of Captopril.
FurazolidoneFurazolidone may increase the hypotensive activities of Captopril.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Captopril.
GarlicThe serum concentration of Captopril can be decreased when it is combined with Garlic.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Captopril.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Captopril.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Captopril.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Captopril.
GuanabenzGuanabenz may increase the hypotensive activities of Captopril.
GuanadrelGuanadrel may increase the hypotensive activities of Captopril.
GuanethidineGuanethidine may increase the hypotensive activities of Captopril.
GuanfacineGuanfacine may increase the hypotensive activities of Captopril.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Captopril.
HaloperidolThe metabolism of Captopril can be decreased when combined with Haloperidol.
HeparinHeparin may increase the hyperkalemic activities of Captopril.
HexamethoniumCaptopril may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Captopril.
HMPL-004The risk or severity of adverse effects can be increased when Captopril is combined with HMPL-004.
HydracarbazineHydracarbazine may increase the hypotensive activities of Captopril.
HydralazineCaptopril may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Captopril.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Captopril.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Captopril.
IbuprofenThe risk or severity of adverse effects can be increased when Captopril is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Captopril is combined with Ibuproxam.
IcatibantIcatibant may decrease the antihypertensive activities of Captopril.
IcatibantThe risk or severity of adverse effects can be increased when Captopril is combined with Icatibant.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Captopril.
IloprostIloprost may increase the hypotensive activities of Captopril.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Captopril.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Captopril.
ImipramineThe metabolism of Captopril can be decreased when combined with Imipramine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Captopril.
IndapamideIndapamide may increase the hypotensive activities of Captopril.
IndenololCaptopril may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Captopril.
IndinavirThe metabolism of Captopril can be decreased when combined with Indinavir.
IndomethacinThe risk or severity of adverse effects can be increased when Captopril is combined with Indomethacin.
IndoprofenThe risk or severity of adverse effects can be increased when Captopril is combined with Indoprofen.
IndoraminCaptopril may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Captopril.
IproniazidIproniazid may increase the hypotensive activities of Captopril.
IrbesartanIrbesartan may increase the hypotensive activities of Captopril.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Captopril.
IronThe risk or severity of adverse effects can be increased when Captopril is combined with Iron.
Iron DextranThe risk or severity of adverse effects can be increased when Captopril is combined with Iron Dextran.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Captopril.
IsoniazidThe metabolism of Captopril can be decreased when combined with Isoniazid.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Captopril.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Captopril.
IsoxicamThe risk or severity of adverse effects can be increased when Captopril is combined with Isoxicam.
IsoxsuprineThe risk or severity of adverse effects can be increased when Captopril is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Captopril.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Captopril.
KebuzoneThe risk or severity of adverse effects can be increased when Captopril is combined with Kebuzone.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Captopril.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Captopril.
KetoconazoleThe metabolism of Captopril can be decreased when combined with Ketoconazole.
KetoprofenThe risk or severity of adverse effects can be increased when Captopril is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Captopril is combined with Ketorolac.
LabetalolLabetalol may increase the hypotensive activities of Captopril.
LacidipineCaptopril may increase the hypotensive activities of Lacidipine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Captopril.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Captopril.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Captopril.
Lanthanum carbonateThe serum concentration of Captopril can be decreased when it is combined with Lanthanum carbonate.
LatanoprostLatanoprost may increase the hypotensive activities of Captopril.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Captopril.
LeflunomideThe risk or severity of adverse effects can be increased when Captopril is combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Captopril.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Captopril.
LercanidipineLercanidipine may increase the hypotensive activities of Captopril.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Captopril.
LevobunololThe risk or severity of adverse effects can be increased when Captopril is combined with Levobunolol.
LevodopaCaptopril may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Captopril.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Captopril.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Captopril.
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Captopril.
LisinoprilLisinopril may increase the hypotensive activities of Captopril.
LithiumThe serum concentration of Lithium can be increased when it is combined with Captopril.
LofexidineCaptopril may increase the hypotensive activities of Lofexidine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Captopril.
LopinavirThe metabolism of Captopril can be decreased when combined with Lopinavir.
LorcaserinThe metabolism of Captopril can be decreased when combined with Lorcaserin.
LornoxicamThe risk or severity of adverse effects can be increased when Captopril is combined with Lornoxicam.
LosartanLosartan may increase the hypotensive activities of Captopril.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Captopril.
LoxoprofenThe risk or severity of adverse effects can be increased when Captopril is combined with Loxoprofen.
LumefantrineThe metabolism of Captopril can be decreased when combined with Lumefantrine.
LumiracoxibThe risk or severity of adverse effects can be increased when Captopril is combined with Lumiracoxib.
MacitentanCaptopril may increase the hypotensive activities of Macitentan.
MagaldrateThe serum concentration of Captopril can be decreased when it is combined with Magaldrate.
Magnesium carbonateThe serum concentration of Captopril can be decreased when it is combined with Magnesium carbonate.
Magnesium hydroxideThe serum concentration of Captopril can be decreased when it is combined with Magnesium hydroxide.
Magnesium oxideThe serum concentration of Captopril can be decreased when it is combined with Magnesium oxide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Captopril is combined with Magnesium salicylate.
Magnesium TrisilicateThe serum concentration of Captopril can be decreased when it is combined with Magnesium Trisilicate.
ManidipineCaptopril may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Captopril.
MasoprocolThe risk or severity of adverse effects can be increased when Captopril is combined with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Captopril.
MecamylamineMecamylamine may increase the hypotensive activities of Captopril.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Captopril is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Captopril is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Captopril is combined with Meloxicam.
MesalazineThe risk or severity of adverse effects can be increased when Captopril is combined with Mesalazine.
MesalazineMesalazine may decrease the antihypertensive activities of Captopril.
MetamizoleThe risk or severity of adverse effects can be increased when Captopril is combined with Metamizole.
MethadoneThe metabolism of Captopril can be decreased when combined with Methadone.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Captopril.
MethohexitalMethohexital may increase the hypotensive activities of Captopril.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Captopril.
MethotrimeprazineThe metabolism of Captopril can be decreased when combined with Methotrimeprazine.
MethyclothiazideMethyclothiazide may increase the hypotensive activities of Captopril.
MethyclothiazideThe risk or severity of adverse effects can be increased when Captopril is combined with Methyclothiazide.
MethyldopaMethyldopa may increase the hypotensive activities of Captopril.
Methylene blueMethylene blue may increase the hypotensive activities of Captopril.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Captopril.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Captopril.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Captopril.
MetipranololCaptopril may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Captopril.
MetoprololMetoprolol may increase the hypotensive activities of Captopril.
MibefradilCaptopril may increase the hypotensive activities of Mibefradil.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Captopril.
MinaprineMinaprine may increase the hypotensive activities of Captopril.
MinoxidilMinoxidil may increase the hypotensive activities of Captopril.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Captopril.
MirabegronThe metabolism of Captopril can be decreased when combined with Mirabegron.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Captopril.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Captopril.
MoclobemideMoclobemide may increase the hypotensive activities of Captopril.
MoexiprilMoexipril may increase the hypotensive activities of Captopril.
MolsidomineMolsidomine may increase the hypotensive activities of Captopril.
MorphineThe serum concentration of Morphine can be increased when it is combined with Captopril.
MoxonidineCaptopril may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Captopril is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Captopril is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Captopril is combined with Nabumetone.
NadololCaptopril may increase the hypotensive activities of Nadolol.
NadroparinNadroparin may increase the hyperkalemic activities of Captopril.
NaftifineThe risk or severity of adverse effects can be increased when Captopril is combined with Naftifine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Captopril.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Captopril.
NaproxenThe risk or severity of adverse effects can be increased when Captopril is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Captopril is combined with NCX 4016.
NebivololCaptopril may increase the hypotensive activities of Nebivolol.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Captopril.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Captopril.
NepafenacThe risk or severity of adverse effects can be increased when Captopril is combined with Nepafenac.
NesiritideThe risk or severity of adverse effects can be increased when Captopril is combined with Nesiritide.
NevirapineThe metabolism of Captopril can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Captopril.
NicardipineNicardipine may increase the hypotensive activities of Captopril.
NicorandilNicorandil may increase the hypotensive activities of Captopril.
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Captopril.
Niflumic AcidThe risk or severity of adverse effects can be increased when Captopril is combined with Niflumic Acid.
NiguldipineCaptopril may increase the hypotensive activities of Niguldipine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Captopril.
NilotinibThe metabolism of Captopril can be decreased when combined with Nilotinib.
NilvadipineCaptopril may increase the hypotensive activities of Nilvadipine.
NimesulideThe risk or severity of adverse effects can be increased when Captopril is combined with Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Captopril.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Captopril.
NisoldipineNisoldipine may increase the hypotensive activities of Captopril.
NitrendipineNitrendipine may increase the hypotensive activities of Captopril.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Captopril.
NitroprussideNitroprusside may increase the hypotensive activities of Captopril.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Captopril.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Captopril.
ObinutuzumabCaptopril may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Captopril.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Captopril.
OlmesartanOlmesartan may increase the hypotensive activities of Captopril.
OlopatadineThe risk or severity of adverse effects can be increased when Captopril is combined with Olopatadine.
OlsalazineThe risk or severity of adverse effects can be increased when Captopril is combined with Olsalazine.
OmapatrilatOmapatrilat may increase the hypotensive activities of Captopril.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Captopril.
OrgoteinThe risk or severity of adverse effects can be increased when Captopril is combined with Orgotein.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Captopril.
OxaprozinThe risk or severity of adverse effects can be increased when Captopril is combined with Oxaprozin.
OxprenololCaptopril may increase the hypotensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Captopril is combined with Oxyphenbutazone.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Captopril.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Captopril.
PanobinostatThe metabolism of Captopril can be decreased when combined with Panobinostat.
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Captopril.
ParecoxibThe risk or severity of adverse effects can be increased when Captopril is combined with Parecoxib.
PargylineCaptopril may increase the hypotensive activities of Pargyline.
ParnaparinParnaparin may increase the hyperkalemic activities of Captopril.
ParoxetineThe metabolism of Captopril can be decreased when combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Captopril.
Peginterferon alfa-2bThe serum concentration of Captopril can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololCaptopril may increase the hypotensive activities of Penbutolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Captopril.
PentoliniumPentolinium may increase the hypotensive activities of Captopril.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Captopril.
PerindoprilPerindopril may increase the hypotensive activities of Captopril.
PethidineThe risk or severity of adverse effects can be increased when Captopril is combined with Pethidine.
PhenelzinePhenelzine may increase the hypotensive activities of Captopril.
PheniprazinePheniprazine may increase the hypotensive activities of Captopril.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Captopril.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Captopril.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Captopril.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Captopril.
PhentolaminePhentolamine may increase the hypotensive activities of Captopril.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Captopril is combined with Phenylbutazone.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Captopril.
PimecrolimusThe risk or severity of adverse effects can be increased when Captopril is combined with Pimecrolimus.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Captopril.
PinacidilCaptopril may increase the hypotensive activities of Pinacidil.
PindololPindolol may increase the hypotensive activities of Captopril.
PiretanidePiretanide may increase the hypotensive activities of Captopril.
PirfenidoneThe risk or severity of adverse effects can be increased when Captopril is combined with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Captopril.
PiroxicamThe risk or severity of adverse effects can be increased when Captopril is combined with Piroxicam.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Captopril.
PivhydrazinePivhydrazine may increase the hypotensive activities of Captopril.
PolythiazideCaptopril may increase the hypotensive activities of Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Captopril.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Captopril.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Captopril.
PrazosinPrazosin may increase the hypotensive activities of Captopril.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Captopril.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Captopril.
PregabalinThe risk or severity of adverse effects can be increased when Captopril is combined with Pregabalin.
PrimidonePrimidone may increase the hypotensive activities of Captopril.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Captopril.
PromazineThe metabolism of Captopril can be decreased when combined with Promazine.
PropacetamolThe risk or severity of adverse effects can be increased when Captopril is combined with Propacetamol.
PropranololPropranolol may increase the hypotensive activities of Captopril.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Captopril.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Captopril.
PTC299The risk or severity of adverse effects can be increased when Captopril is combined with PTC299.
QuetiapineThe risk or severity of adverse effects can be increased when Captopril is combined with Quetiapine.
QuinaprilQuinapril may increase the hypotensive activities of Captopril.
QuinethazoneQuinethazone may increase the hypotensive activities of Captopril.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Captopril.
QuinidineThe metabolism of Captopril can be decreased when combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Captopril.
QuinineThe serum concentration of Quinine can be increased when it is combined with Captopril.
RamiprilRamipril may increase the hypotensive activities of Captopril.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Captopril.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Captopril.
RanolazineThe metabolism of Captopril can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the hypotensive activities of Captopril.
RemikirenRemikiren may increase the hypotensive activities of Captopril.
RescinnamineCaptopril may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Captopril.
ResveratrolThe risk or severity of adverse effects can be increased when Captopril is combined with Resveratrol.
ReviparinReviparin may increase the hyperkalemic activities of Captopril.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Captopril.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Captopril.
RiociguatCaptopril may increase the hypotensive activities of Riociguat.
RisperidoneCaptopril may increase the hypotensive activities of Risperidone.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Captopril.
RitonavirThe metabolism of Captopril can be decreased when combined with Ritonavir.
RituximabCaptopril may increase the hypotensive activities of Rituximab.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Captopril.
RofecoxibThe risk or severity of adverse effects can be increased when Captopril is combined with Rofecoxib.
RolapitantThe metabolism of Captopril can be decreased when combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Captopril.
RopiniroleThe metabolism of Captopril can be decreased when combined with Ropinirole.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Captopril.
SacubitrilThe risk or severity of adverse effects can be increased when Captopril is combined with Sacubitril.
SafrazineSafrazine may increase the hypotensive activities of Captopril.
SalicylamideThe risk or severity of adverse effects can be increased when Captopril is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Captopril is combined with Salicylic acid.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Captopril.
SalsalateThe risk or severity of adverse effects can be increased when Captopril is combined with Salsalate.
SaprisartanCaptopril may increase the hypotensive activities of Saprisartan.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Captopril.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Captopril.
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Captopril.
SecobarbitalSecobarbital may increase the hypotensive activities of Captopril.
SelegilineSelegiline may increase the hypotensive activities of Captopril.
SelexipagCaptopril may increase the hypotensive activities of Selexipag.
SeratrodastThe risk or severity of adverse effects can be increased when Captopril is combined with Seratrodast.
SertralineThe metabolism of Captopril can be decreased when combined with Sertraline.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Captopril.
SildenafilSildenafil may increase the antihypertensive activities of Captopril.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Captopril.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Captopril.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Captopril.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Captopril.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Captopril.
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Captopril.
SitaxentanCaptopril may increase the hypotensive activities of Sitaxentan.
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Captopril is combined with Sodium aurothiomalate.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Captopril.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Captopril.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Captopril.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Captopril.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Captopril.
SpiraprilCaptopril may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Captopril.
SRT501The risk or severity of adverse effects can be increased when Captopril is combined with SRT501.
St. John's WortThe metabolism of Captopril can be increased when combined with St. John's Wort.
StiripentolThe metabolism of Captopril can be decreased when combined with Stiripentol.
SulfasalazineThe risk or severity of adverse effects can be increased when Captopril is combined with Sulfasalazine.
SulindacThe risk or severity of adverse effects can be increased when Captopril is combined with Sulindac.
SuprofenThe risk or severity of adverse effects can be increased when Captopril is combined with Suprofen.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Captopril.
TadalafilTadalafil may increase the antihypertensive activities of Captopril.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Captopril.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Captopril.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Captopril.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Captopril.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Captopril.
TelmisartanTelmisartan may increase the hypotensive activities of Captopril.
TemocaprilCaptopril may increase the hypotensive activities of Temocapril.
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Captopril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Captopril.
TenoxicamThe risk or severity of adverse effects can be increased when Captopril is combined with Tenoxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Captopril is combined with Tepoxalin.
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Captopril.
TerbinafineThe metabolism of Captopril can be decreased when combined with Terbinafine.
TeriflunomideThe risk or severity of adverse effects can be increased when Captopril is combined with Teriflunomide.
TerlipressinCaptopril may increase the hypotensive activities of Terlipressin.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Captopril.
ThiamylalThiamylal may increase the hypotensive activities of Captopril.
ThiopentalThiopental may increase the hypotensive activities of Captopril.
ThioridazineThe metabolism of Captopril can be decreased when combined with Thioridazine.
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Captopril.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Captopril is combined with Tiaprofenic acid.
TiboloneCaptopril may increase the hypotensive activities of Tibolone.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Captopril.
TiclopidineThe metabolism of Captopril can be decreased when combined with Ticlopidine.
TicrynafenCaptopril may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Captopril.
TinzaparinTinzaparin may increase the hyperkalemic activities of Captopril.
TipranavirThe serum concentration of Captopril can be decreased when it is combined with Tipranavir.
TizanidineTizanidine may increase the hypotensive activities of Captopril.
TizanidineThe risk or severity of adverse effects can be increased when Captopril is combined with Tizanidine.
TolazolineTolazoline may increase the hypotensive activities of Captopril.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Captopril is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Captopril is combined with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Captopril.
TolvaptanTolvaptan may increase the hyperkalemic activities of Captopril.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Captopril.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Captopril.
TorasemideTorasemide may increase the hypotensive activities of Captopril.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Captopril.
TrandolaprilTrandolapril may increase the hypotensive activities of Captopril.
TranilastThe risk or severity of adverse effects can be increased when Captopril is combined with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Captopril.
TranylcypromineTranylcypromine may increase the hypotensive activities of Captopril.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Captopril.
TravoprostTravoprost may increase the hypotensive activities of Captopril.
TreprostinilTreprostinil may increase the hypotensive activities of Captopril.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Captopril.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Captopril.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Captopril.
TrimazosinCaptopril may increase the hypotensive activities of Trimazosin.
TrimethaphanTrimethaphan may increase the hypotensive activities of Captopril.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Captopril.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Captopril.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Captopril is combined with Trisalicylate-choline.
UdenafilUdenafil may increase the antihypertensive activities of Captopril.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Captopril.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Captopril.
UnoprostoneCaptopril may increase the hypotensive activities of Unoprostone.
ValdecoxibThe risk or severity of adverse effects can be increased when Captopril is combined with Valdecoxib.
ValsartanValsartan may increase the hypotensive activities of Captopril.
VardenafilVardenafil may increase the antihypertensive activities of Captopril.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Captopril.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Captopril.
VenlafaxineThe metabolism of Captopril can be decreased when combined with Venlafaxine.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Captopril.
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Captopril.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Captopril.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Captopril.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Captopril.
XylometazolineCaptopril may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Captopril.
ZaltoprofenThe risk or severity of adverse effects can be increased when Captopril is combined with Zaltoprofen.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Captopril.
ZileutonThe risk or severity of adverse effects can be increased when Captopril is combined with Zileuton.
ZiprasidoneThe metabolism of Captopril can be decreased when combined with Ziprasidone.
ZomepiracThe risk or severity of adverse effects can be increased when Captopril is combined with Zomepirac.
Food Interactions
  • Captopril decreases the excretion of potassium. Salt substitutes containing potassium increase the risk of hyperkalemia.
  • Food decreases absorption by 25 - 40%. Clinical significance is debatable.
  • Herbs that may attenuate the antihypertensive effect of captopril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of captopril.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Andujar-Sanchez M, Jara-Perez V, Camara-Artigas A: Thermodynamic determination of the binding constants of angiotensin-converting enzyme inhibitors by a displacement method. FEBS Lett. 2007 Jul 24;581(18):3449-54. Epub 2007 Jun 27. [PubMed:17618628 ]
  2. Dalkas GA, Marchand D, Galleyrand JC, Martinez J, Spyroulias GA, Cordopatis P, Cavelier F: Study of a lipophilic captopril analogue binding to angiotensin I converting enzyme. J Pept Sci. 2010 Feb;16(2):91-7. doi: 10.1002/psc.1201. [PubMed:20014331 ]
  3. Natesh R, Schwager SL, Evans HR, Sturrock ED, Acharya KR: Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry. 2004 Jul 13;43(27):8718-24. [PubMed:15236580 ]
  4. Piepho RW: Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000 Oct 1;57 Suppl 1:S3-7. [PubMed:11030016 ]
  5. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321 ]
  6. Tzakos AG, Naqvi N, Comporozos K, Pierattelli R, Theodorou V, Husain A, Gerothanassis IP: The molecular basis for the selection of captopril cis and trans conformations by angiotensin I converting enzyme. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5084-7. Epub 2006 Aug 2. [PubMed:16889963 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Ubiquitinous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture. As well as degrading extracellular matrix proteins, can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction. Also cleaves KISS at a Gly...
Gene Name:
MMP2
Uniprot ID:
P08253
Molecular Weight:
73881.695 Da
References
  1. Brower GL, Levick SP, Janicki JS: Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure. Am J Physiol Heart Circ Physiol. 2007 Jun;292(6):H3057-64. Epub 2007 Feb 16. [PubMed:17308006 ]
  2. Okada M, Kikuzuki R, Harada T, Hori Y, Yamawaki H, Hara Y: Captopril attenuates matrix metalloproteinase-2 and -9 in monocrotaline-induced right ventricular hypertrophy in rats. J Pharmacol Sci. 2008 Dec;108(4):487-94. Epub 2008 Dec 5. [PubMed:19057128 ]
  3. Prontera C, Mariani B, Rossi C, Poggi A, Rotilio D: Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer. 1999 May 31;81(5):761-6. [PubMed:10328230 ]
  4. Reinhardt D, Sigusch HH, Hensse J, Tyagi SC, Korfer R, Figulla HR: Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart. 2002 Nov;88(5):525-30. [PubMed:12381651 ]
  5. Williams RN, Parsons SL, Morris TM, Rowlands BJ, Watson SA: Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models. Eur J Surg Oncol. 2005 Nov;31(9):1042-50. Epub 2005 Jul 1. [PubMed:15993560 ]
  6. Yamamoto D, Takai S, Hirahara I, Kusano E: Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy. Clin Chim Acta. 2010 May 2;411(9-10):762-4. doi: 10.1016/j.cca.2010.02.059. Epub 2010 Feb 22. [PubMed:20184869 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
May play an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly-|-Leu bond. Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments. Degrades fibronectin but not laminin or Pz-peptide.
Gene Name:
MMP9
Uniprot ID:
P14780
Molecular Weight:
78457.51 Da
References
  1. Okada M, Kikuzuki R, Harada T, Hori Y, Yamawaki H, Hara Y: Captopril attenuates matrix metalloproteinase-2 and -9 in monocrotaline-induced right ventricular hypertrophy in rats. J Pharmacol Sci. 2008 Dec;108(4):487-94. Epub 2008 Dec 5. [PubMed:19057128 ]
  2. Reinhardt D, Sigusch HH, Hensse J, Tyagi SC, Korfer R, Figulla HR: Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart. 2002 Nov;88(5):525-30. [PubMed:12381651 ]
  3. Williams RN, Parsons SL, Morris TM, Rowlands BJ, Watson SA: Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models. Eur J Surg Oncol. 2005 Nov;31(9):1042-50. Epub 2005 Jul 1. [PubMed:15993560 ]
  4. Yamamoto D, Takai S, Miyazaki M: Inhibitory profiles of captopril on matrix metalloproteinase-9 activity. Eur J Pharmacol. 2008 Jul 7;588(2-3):277-9. doi: 10.1016/j.ejphar.2008.04.031. Epub 2008 May 22. [PubMed:18501888 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Epoxide hydrolase that catalyzes the final step in the biosynthesis of the proinflammatory mediator leukotriene B4. Has also aminopeptidase activity.
Gene Name:
LTA4H
Uniprot ID:
P09960
Molecular Weight:
69284.64 Da
References
  1. Thunnissen MM, Andersson B, Samuelsson B, Wong CH, Haeggstrom J: Crystal structures of leukotriene A4 hydrolase in complex with captopril and two competitive tight-binding inhibitors. FASEB J. 2002 Oct;16(12):1648-50. Epub 2002 Aug 7. [PubMed:12207002 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
other/unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Keire DA, Mariappan SV, Peng J, Rabenstein DL: Nuclear magnetic resonance studies of the binding of captopril and penicillamine by serum albumin. Biochem Pharmacol. 1993 Sep 14;46(6):1059-69. [PubMed:8216349 ]
  2. Lin SY, Wei YS, Li MJ, Wang SL: Effect of ethanol or/and captopril on the secondary structure of human serum albumin before and after protein binding. Eur J Pharm Biopharm. 2004 May;57(3):457-64. [PubMed:15093593 ]
  3. Mariee AD, Al-Shabanah O: Protective ability and binding affinity of captopril towards serum albumin in an in vitro glycation model of diabetes mellitus. J Pharm Biomed Anal. 2006 May 3;41(2):571-5. Epub 2006 Feb 15. [PubMed:16469467 ]
  4. Narazaki R, Harada K, Sugii A, Otagiri M: Kinetic analysis of the covalent binding of captopril to human serum albumin. J Pharm Sci. 1997 Feb;86(2):215-9. [PubMed:9040098 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Watanabe K, Sawano T, Terada K, Endo T, Sakata M, Sato J: Studies on intestinal absorption of sulpiride (1): carrier-mediated uptake of sulpiride in the human intestinal cell line Caco-2. Biol Pharm Bull. 2002 Jul;25(7):885-90. [PubMed:12132663 ]
  2. Temple CS, Boyd CA: Proton-coupled oligopeptide transport by rat renal cortical brush border membrane vesicles: a functional analysis using ACE inhibitors to determine the isoform of the transporter. Biochim Biophys Acta. 1998 Aug 14;1373(1):277-81. [PubMed:9733984 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Kuze K, Graves P, Leahy A, Wilson P, Stuhlmann H, You G: Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells. J Biol Chem. 1999 Jan 15;274(3):1519-24. [PubMed:9880528 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23